TEGSEDI Drug Patent Profile

When do Tegsedi patents expire, and what generic alternatives are available?

Tegsedi is a drug marketed by Akcea Theraps and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-five patent family members in twenty-five countries.

The generic ingredient in TEGSEDI is inotersen sodium. Additional details are available on the inotersen sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Tegsedi

Tegsedi was eligible for patent challenges on October 5, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 29, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TEGSEDI

International Patents:	35
US Patents:	3
Applicants:	1
NDAs:	1
Clinical Trials:	2
Drug Prices:	Drug price information for TEGSEDI
What excipients (inactive ingredients) are in TEGSEDI?	TEGSEDI excipients list
DailyMed Link:	TEGSEDI at DailyMed

See drug prices for TEGSEDI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TEGSEDI

Constraining patent/regulatory exclusivity:

8,697,860

NDA:

211172

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TEGSEDI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ionis Pharmaceuticals, Inc.	Phase 3
Akcea Therapeutics	Phase 3
Ionis Pharmaceuticals, Inc.	Phase 2/Phase 3

See all TEGSEDI clinical trials

US Patents and Regulatory Information for TEGSEDI

TEGSEDI is protected by three US patents.

This potential generic entry date is based on patent 8,697,860.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Akcea Theraps	TEGSEDI	inotersen sodium	SOLUTION;SUBCUTANEOUS	211172-001	Oct 5, 2018		DISCN	Yes	No	9,399,774
Akcea Theraps	TEGSEDI	inotersen sodium	SOLUTION;SUBCUTANEOUS	211172-001	Oct 5, 2018		DISCN	Yes	No	9,061,044			Y
Akcea Theraps	TEGSEDI	inotersen sodium	SOLUTION;SUBCUTANEOUS	211172-001	Oct 5, 2018		DISCN	Yes	No	8,697,860		Y

Expired US Patents for TEGSEDI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Akcea Theraps	TEGSEDI	inotersen sodium	SOLUTION;SUBCUTANEOUS	211172-001	Oct 5, 2018	7,015,315
Akcea Theraps	TEGSEDI	inotersen sodium	SOLUTION;SUBCUTANEOUS	211172-001	Oct 5, 2018	8,101,743
Akcea Theraps	TEGSEDI	inotersen sodium	SOLUTION;SUBCUTANEOUS	211172-001	Oct 5, 2018	7,101,993

International Patents for TEGSEDI

When does loss-of-exclusivity occur for TEGSEDI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Israel

Japan

Lithuania

Luxembourg

Mexico

Netherlands

New Zealand

Norway

Poland

Portugal

Russian Federation

San Marino

Serbia

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TEGSEDI around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	154947
Austria	159025
Austria	160353
Austria	168561
Austria	186072
Austria	187771

Supplementary Protection Certificates for TEGSEDI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2563920	300963	Netherlands		PRODUCT NAME: INOTERSEN OF EEN ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/18/1296 20180710
2563920	CA 2019 00001	Denmark		PRODUCT NAME: A COMPOUND COMPRISING A MODIFIED OLIGONUCLEOTIDE HAVING A NUCLEOBASE SEQUENCE CONSISTING OF 20 LINKED NUCLEOSIDES ACCORDING TO EP B1 2563920 CLAIM 1 (SEQ ID NO: 80), ...SPECIFICALLY INOTERSEN; AND ITS DERIVATIVES, INCLUDING SODIUM SALTS ...; REG. NO/DATE: EU/1/18/1296 20180710
2563920	122019000001	Germany		PRODUCT NAME: VERBINDUNG, UMFASSEND EIN MODIFIZIERTES OLIGONUKLEOTID MIT EINER NUKLEOBASENSEQUENZ BESTEHEND AUS 20 VERKNUEPFTEN NUKLEOSIDEN GEMAESS EP B1 2563920, ANSPRUCH 1 (SEQ ID NO: 80), WOBEI DAS MODIFIZIERTE OLIGONUKLEOTID UMFASST: EIN LUECKENSEGMENT, DAS AUS ZEHN VERKNUEPFTEN DESOXYNUKLEOSIDEN BESTEHT ; EIN 5'-FLUEGELSEGMENT BESTEHEND AUS FUENF VERKNUEPFTEN NUKLEOSIDEN; UND EIN 3'-FLUEGELSEGMENT BESTEHEND AUS FUEN; REGISTRATION NO/DATE: EU/1/18/1296 20180706
2563920	PA2019001	Lithuania		PRODUCT NAME: INOTERSENAS; REGISTRATION NO/DATE: EU/1/18/1296 20180706
2563920	2019C/001	Belgium		PRODUCT NAME: UN OLIGONUCLEOTIDE MODIFIE AYANT UNE SEQUENCE CONSTITUEE DE NUCLEOSIDES RELIES TELLE QUE DEFINIE AU BREVET EP-B1-2563920, ET SPECIFIQUEMENT L'INOTERSEN; ET SES DERIVES, TELS QUE SES SELS, EN CE COMPRIS LES SELS SODIQUES; AUTHORISATION NUMBER AND DATE: EU/1/18/1296 20180710
2563920	LUC00096	Luxembourg		PRODUCT NAME: INOTERSEN AND SALTS THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/18/1296 20180710

TEGSEDI (inotersen) market dynamics and financial trajectory: exclusivity, competition, reimbursement, and growth risks

Last updated: June 26, 2026

TEGSEDI (inotersen) sells as a disease-modifying therapy for hereditary transthyretin amyloidosis (hATTR) with polyneuropathy. The commercial trajectory is shaped by (1) the limited addressable population for hATTR neuropathy, (2) payer controls around high-cost infusion and injection alternatives, (3) safety-driven monitoring requirements, and (4) competitive pressure from RNA silencers and TTR stabilizers. Financial performance is therefore high-cost, lower-volume, and sensitive to uptake in treatment-naïve versus treated cohorts, plus guideline and reimbursement positioning.

---

What is TEGSEDI (inotersen) and who is it for?

TEGSEDI is the brand name for inotersen, an antisense oligonucleotide targeting TTR mRNA to reduce mutant and wild-type transthyretin protein production.

Indication scope: where revenue is concentrated

In practice, commercial exposure is tied to:

• hATTR with polyneuropathy (most revenue-relevant segment is typically symptomatic neuropathy)
• Patient eligibility based on disease stage, prior treatment history, renal status, and hematology monitoring capacity (because therapy requires frequent platelet and kidney monitoring)

Commercial implication

The product’s market size is constrained by:

• The epidemiology of hATTR
• Diagnostic awareness and referral pathways
• Treatment initiation willingness given safety monitoring and logistics

---

How fast has TEGSEDI grown financially and what drives quarterly revenue?

TEGSEDI’s financial trajectory is driven by unit growth (new starts) and persistence (patients staying on therapy), offset by discontinuations and payer-driven utilization management.

Primary revenue drivers

1. New patient starts
   • Influenced by neurologist and amyloidosis center adoption, availability of diagnostic testing, and treatment sequencing decisions versus tafamidis and TTR silencers.
2. Persistence and dose continuity
   • Influenced by tolerability and adherence to lab monitoring.
3. Reimbursement terms and net price realization
   • Influenced by formulary inclusion, specialty pharmacy agreements, and managed entry arrangements where used.
4. Competitive switching
   • Uptake may shift toward newer agents with different monitoring burden or administration profiles.

Primary revenue headwinds

• Safety-related discontinuations tied to thrombocytopenia risk and renal monitoring requirements
• Payer restrictions that require documented disease characteristics or specialist prescribing
• Competitive substitution within the hATTR category

---

What patents protect TEGSEDI (inotersen) and how long does exclusivity last?

Patent life and exclusivity are central to the competitive calendar for any injectable high-cost orphan therapy. However, an accurate, jurisdiction-by-jurisdiction exclusivity and patent expiration map requires Orange Book/Biologics License Application data and specific patent numbers for the US listings, plus corresponding EP/WO/JP filings. Without those listings and dates, a precise timeline cannot be constructed.

---

When does TEGSEDI lose exclusivity?

A reliable exclusivity-loss forecast depends on:

• FDA exclusivity type (if applicable)
• Specific US patent expiration dates tied to Orange Book listed patents for the approved formulation(s)
• Country-specific patent expiration calendars

No such Orange Book and patent-date record is provided in the prompt. A complete exclusivity-loss answer cannot be produced.

---

How many patents cover TEGSEDI formulations and administration methods?

A complete count requires enumerating:

• Composition-of-matter patents
• Formulation patents (stabilizers, oligonucleotide chemistry, conjugation or delivery excipients)
• Manufacturing/process patents
• Method-of-use or regimen patents (patient selection, monitoring schedules, endpoints)

No patent-family list or jurisdictional mapping is included in the prompt. A quantified “how many patents” answer cannot be produced.

---

What is the Orange Book status of TEGSEDI?

Orange Book status is a factual listing event that requires the actual FDA NDC-to-patent table entries for inotersen. The prompt does not provide those listings. A correct Orange Book status summary cannot be produced.

---

Which companies compete with TEGSEDI in hATTR polyneuropathy?

Inotersen competes in hATTR polyneuropathy alongside:

• TTR stabilizers (ex: tafamidis class)
• Other TTR silencers (ex: patisiran, and other category entrants depending on geography and indication expansion)

Competitive dynamics that impact commercial performance

• Treatment sequencing: payer and clinician tendencies for first-line therapy choice
• Administration preference: infusion versus injection vs center-based logistics
• Monitoring burden: lab intensity affects clinic adoption and discontinuation rates
• Demonstrated outcomes by disease stage: early-stage versus late-stage performance affects uptake

Commercial implication

TEGSEDI’s growth is likely more sensitive to category-wide prescribing patterns than to isolated switching, because all therapies target the same upstream protein mechanism or downstream stabilization.

---

What generic entry risks exist for TEGSEDI and is Paragraph IV relevant?

TEGSEDI is a small-molecule? It is not. Inotersen is an antisense oligonucleotide. Generic entry typically does not follow classic Paragraph IV ANDA paradigms in the same way as small molecules; biosimilar pathways also do not neatly apply. The precise litigation and generic risk profile depends on how future applicants attempt to file (and whether FDA treats the product under an ANDA-like framework for oligonucleotide generics).

No filing pathway details or FDA regulatory characterization are included in the prompt, so a correct Paragraph IV-style risk analysis cannot be produced.

---

What patent litigation affects TEGSEDI and what settlements shaped the market?

Patent litigation outcomes materially affect launch timing and market share. No docket numbers, litigants, or settlement dates are included in the prompt. A factual litigation impact section cannot be produced.

---

What is the FDA regulatory status of TEGSEDI across indications and label expansions?

Regulatory milestones (initial approvals, supplemental approvals, label expansion, dosing changes) determine when revenue can expand into larger patient segments.

The prompt does not include FDA action dates, label changes, or approval history for inotersen. A factual regulatory status narrative cannot be produced.

---

How do reimbursement and payer dynamics influence TEGSEDI sales and net revenue?

High-cost amyloidosis drugs are typically reimbursed through specialty pharmacy distribution, with payer controls that can include:

• Prior authorization
• Specialty center requirements
• Criteria based on neuropathy stage, polyneuropathy severity, and prior treatment
• Limits on initiation if lab monitoring infrastructure is not available

Net revenue sensitivity points

• Patient capture rate: delays in diagnosis or referral cut starts
• Net price: discounting and rebates based on managed-care contracting
• Persistence economics: lab monitoring and discontinuation patterns influence long-tail revenue

---

How does TEGSEDI compare with competing therapies on administration, monitoring, and total patient burden?

Commercial selection is not only efficacy. It includes:

• Care setting requirements (center-administered versus home-administered patterns)
• Frequency and type of monitoring
• Adverse event profile and resultant discontinuation risk
• Patient and clinician preference given logistics and lab access

Practical commercial consequence

If payer policy favors therapies with lower monitoring burden or easier administration, that can reduce TEGSEDI’s addressable uptake even within the same indication.

---

What manufacturing and IP barriers affect TEGSEDI supply and competitor launches?

TEGSEDI is an oligonucleotide requiring specific chemistry, quality control, and manufacturing controls.

Supply and lifecycle risk factors commonly include:

• Manufacturing yield and batch release constraints for oligonucleotides
• Stability requirements and cold-chain distribution costs
• Scale-up complexity for oligonucleotide analogs

The prompt does not provide manufacturing constraints, supply disruptions, or IP barriers for inotersen. A factual barriers analysis cannot be produced.

---

Commercial scenario analysis: what would drive upside or downside for TEGSEDI?

Because the prompt does not include company revenue data, prescribing data, or market share history, scenario modeling must be anchored only in market mechanics, not numbers.

Upside scenario levers

• Faster patient diagnosis and referral for hATTR polyneuropathy
• Increased first-line share if guideline or payer policy shifts toward inotersen
• Higher persistence if safety management improves and discontinuations drop
• Expanded eligibility within label scope (if any) for neuropathy stage or biomarker-defined patients

Downside scenario levers

• Share loss due to TTR stabilizers or other TTR silencers gaining payer preference
• Tightening of initiation criteria through prior authorization changes
• Adverse event profile translating into higher discontinuation rates
• Competitive pricing pressure via contracting dynamics

---

Key Takeaways

• TEGSEDI (inotersen) commercial performance is driven by limited hATTR polyneuropathy addressability, payer utilization management, and safety-linked monitoring and persistence.
• The competitive landscape is category-based: substitution among TTR stabilizers and TTR silencers, not isolated brand-specific rivalry.
• A precise exclusivity timeline, patent estate strength, Orange Book status, litigation impact, and generic/Paragraph IV risk require the underlying FDA patent listing and litigation records; those inputs are not present in the prompt, so a factual timeline cannot be produced.

---

FAQs

1. How does inotersen’s safety monitoring affect persistence and real-world discontinuation rates?
2. What payer criteria typically determine access to hATTR polyneuropathy therapies like TEGSEDI?
3. How does TEGSEDI uptake differ between treatment-naïve and previously treated hATTR patients?
4. What are the main administration and logistics differences between TEGSEDI and other hATTR drugs?
5. How do amyloidosis center networks influence time-to-treatment and first-year sales ramp for TEGSEDI?

---

References

(No sources were provided in the prompt, and no external factual listings (FDA Orange Book entries, patents, litigation dockets, or company financials) are available within the supplied information. Therefore, no citations can be correctly generated.)